VCH-222

Vertex Pharmaceuticals Incorporated · Phase 1 active Small molecule

At a glance

Generic name	VCH-222
Sponsor	Vertex Pharmaceuticals Incorporated
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection (PHASE1, PHASE2)
Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VCH-222 CI brief — competitive landscape report
VCH-222 updates RSS · CI watch RSS
Vertex Pharmaceuticals Incorporated portfolio CI